Chelsea’s business development strategy is to balance the
product development portfolio with early (preclinical) and late-stage
(clinical) product through a combination of product acquisitions
and partnering with pharmaceutical and biotechnology companies to
optimize internal resources and shareholder value.
Our primary business is the acquisition, development and commercialization
of products for the treatment of important unmet medical needs, including
autoimmune diseases, inflammatory diseases and cancer. Chelsea
continues to identify potential business partners (both in-licensing
and out-licensing) with a similar vision of creating innovative products
for the medical community and continued growth of the company.